ERBB2 and neoplasm: To evaluate the accumulation of the alpha-emitting HER2-TTC and its decay product radium-223 in bone, non-tumor-bearing and BT-474 tumor-bearing tibias were collected 14 days after treatment with HER2-TTC at 250 kBq/kg or 500 kBq/kg and analyzed via alpha camera imaging.